125 related articles for article (PubMed ID: 34032711)
1. Diagnostic value of serum human epididymis protein 4 and cancer antigen 125 in the patients with ovarian carcinoma: A protocol for systematic review and meta-analysis.
Dai HY; Hu F; Ding Y
Medicine (Baltimore); 2021 May; 100(21):e25981. PubMed ID: 34032711
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic accuracy of CA125 and HE4 in ovarian carcinoma patients and the effect of confounders on their serum levels.
Ahmed AA; Abdou AM
Curr Probl Cancer; 2019 Oct; 43(5):450-460. PubMed ID: 30670303
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic measures comparison for ovarian malignancy risk in Epithelial ovarian cancer patients: a meta-analysis.
Suri A; Perumal V; Ammalli P; Suryan V; Bansal SK
Sci Rep; 2021 Aug; 11(1):17308. PubMed ID: 34453074
[TBL] [Abstract][Full Text] [Related]
4. Assessment of peritoneal microbial features and tumor marker levels as potential diagnostic tools for ovarian cancer.
Miao R; Badger TC; Groesch K; Diaz-Sylvester PL; Wilson T; Ghareeb A; Martin JA; Cregger M; Welge M; Bushell C; Auvil L; Zhu R; Brard L; Braundmeier-Fleming A
PLoS One; 2020; 15(1):e0227707. PubMed ID: 31917801
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic values of osteopontin combined with CA125 for ovarian cancer: a meta-analysis.
Lan Z; Fu D; Yu X; Xi M
Fam Cancer; 2016 Apr; 15(2):221-30. PubMed ID: 26458935
[TBL] [Abstract][Full Text] [Related]
6. Magnetic resonance imaging for evaluating tumor resectability in advanced ovarian cancer: A protocol for systematic review and meta-analysis.
Liu P; Deng L; Yang L; Yuan X; Xia W; Su Y
Medicine (Baltimore); 2020 Dec; 99(50):e23419. PubMed ID: 33327269
[TBL] [Abstract][Full Text] [Related]
7. Performance of preoperative plasma tumor markers HE4 and CA125 in predicting ovarian cancer mortality in women with epithelial ovarian cancer.
Furrer D; Grégoire J; Turcotte S; Plante M; Bachvarov D; Trudel D; Têtu B; Douville P; Bairati I
PLoS One; 2019; 14(6):e0218621. PubMed ID: 31220149
[TBL] [Abstract][Full Text] [Related]
8. Serum Human Epididymis Protein 4 Combined with Carbohydrate Antigen 125 for Endometrial Carcinoma Diagnosis: A Meta-Analysis and Systematic Review.
Huang GQ; Xi YY; Zhang CJ; Jiang X
Genet Test Mol Biomarkers; 2019 Aug; 23(8):580-588. PubMed ID: 31373853
[No Abstract] [Full Text] [Related]
9. Clinical Usefulness of Cancer Antigen (CA) 125, Human Epididymis 4, and CA72-4 Levels and Risk of Ovarian Malignancy Algorithm Values for Diagnosing Ovarian Tumors in Korean Patients With and Without Endometriosis.
Shin KH; Kim HH; Kwon BS; Suh DS; Joo JK; Kim KH
Ann Lab Med; 2020 Jan; 40(1):40-47. PubMed ID: 31432638
[TBL] [Abstract][Full Text] [Related]
10. Serum human epididymis protein 4 vs carbohydrate antigen 125 for ovarian cancer diagnosis: a systematic review.
Ferraro S; Braga F; Lanzoni M; Boracchi P; Biganzoli EM; Panteghini M
J Clin Pathol; 2013 Apr; 66(4):273-81. PubMed ID: 23426716
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass.
Karlsen MA; Sandhu N; Høgdall C; Christensen IJ; Nedergaard L; Lundvall L; Engelholm SA; Pedersen AT; Hartwell D; Lydolph M; Laursen IA; Høgdall EV
Gynecol Oncol; 2012 Nov; 127(2):379-83. PubMed ID: 22835718
[TBL] [Abstract][Full Text] [Related]
12. Magnetic resonance imaging for the non-invasive diagnosis in patients with ovarian cancer: A protocol for systematic review and meta-analysis.
Su Y; Deng L; Yang L; Yuan X; Xia W; Liu P
Medicine (Baltimore); 2020 Dec; 99(50):e23551. PubMed ID: 33327306
[TBL] [Abstract][Full Text] [Related]
13. Comparison of HE 4, CA 125, ROMA score and ultrasound score in the differential diagnosis of ovarian masses.
Aslan K; Onan MA; Yilmaz C; Bukan N; Erdem M
J Gynecol Obstet Hum Reprod; 2020 May; 49(5):101713. PubMed ID: 32084612
[TBL] [Abstract][Full Text] [Related]
14. The power of the Risk of Ovarian Malignancy Algorithm considering menopausal status: a comparison with CA 125 and HE4.
Han KH; Park NH; Kim JJ; Kim S; Kim HS; Lee M; Song YS
J Gynecol Oncol; 2019 Nov; 30(6):e83. PubMed ID: 31576682
[TBL] [Abstract][Full Text] [Related]
15. The diagnostic accuracy of human epididymis protein 4 (HE4) for discriminating between benign and malignant pelvic masses: a systematic review and meta-analysis.
Olsen M; Lof P; Stiekema A; van den Broek D; Wilthagen EA; Bossuyt PM; Lok CAR
Acta Obstet Gynecol Scand; 2021 Oct; 100(10):1788-1799. PubMed ID: 34212386
[TBL] [Abstract][Full Text] [Related]
16. CPH-I and HE4 Are More Favorable Than CA125 in Differentiating Borderline Ovarian Tumors from Epithelial Ovarian Cancer at Early Stages.
Wang Z; Tao X; Ying C
Dis Markers; 2019; 2019():6241743. PubMed ID: 31737130
[TBL] [Abstract][Full Text] [Related]
17. A multiplex biomarker assay improves the diagnostic performance of HE4 and CA125 in ovarian tumor patients.
Leandersson P; Åkesson A; Hedenfalk I; Malander S; Borgfeldt C
PLoS One; 2020; 15(10):e0240418. PubMed ID: 33075095
[TBL] [Abstract][Full Text] [Related]
18. HE4 combined with CA125: favorable screening tool for ovarian cancer.
Ghasemi N; Ghobadzadeh S; Zahraei M; Mohammadpour H; Bahrami S; Ganje MB; Rajabi S
Med Oncol; 2014 Jan; 31(1):808. PubMed ID: 24323399
[TBL] [Abstract][Full Text] [Related]
19. Comparison of CA125, HE4, and ROMA index for ovarian cancer diagnosis.
Zhang L; Chen Y; Wang K
Curr Probl Cancer; 2019 Apr; 43(2):135-144. PubMed ID: 30017407
[TBL] [Abstract][Full Text] [Related]
20. Review of biomarker systems as an alternative for early diagnosis of ovarian carcinoma.
Srivastava A; Gupta A; Patidar S
Clin Transl Oncol; 2021 Oct; 23(10):1967-1978. PubMed ID: 33840014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
